ArticleScientific reports2025
Functional and molecular single-cell analyses implicate PRDM14 in the initiation of B cell leukemia in mice.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The transcription factor Prdm14 is a potent oncogene implicated in the initiation of many cancers. PRDM14 resets and maintains the pluripotent state in normal cells, but the molecular mechanisms through which PRDM14 drives oncogenesis are poorly understood. Here, we interrogated the heterogeneity of Prdm14-expressing cells in a T cell lymphoblastic leukemia/lymphoma mouse model. Using mass cytometry (CyTOF) of bone marrow at a pre-leukemic timepoint, an unexpected abnormal progenitor B cell population was identified. Prdm14-expressing progenitor B cells demonstrated short-term self-renewal and a block in differentiation when transferred to syngeneic hosts. Consistently, aged host mice succumb to a highly penetrant B-LL. Single-cell RNA-seq analyses suggests that the expression signature of these pre-leukemia cells is more consistent with that of B-1 cells than B-2 cells. B-1 cells are a self-renewing population of unconventional B cells established during embryonic development. Overlaying the chromatin binding of transcriptional marks H3K4me1 and H3K4me3 with PRDM14 suggests that PRDM14 initiates cancers through promiscuous DNA binding, activating oncogenic pathways and skewing development towards a self-renewing B-1-like phenotype. Together, our data show that Prdm14 can initiate premature T and B cell cancer programs when expressed in hematopoietic progenitor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.